Background Despite the chronicity of psoriasis, most systematic reviews focus on short‐term
treatment. Methods The systematic search strategy and results from the German Psoriasis …

Objectives To assess the comparability of the trials included in network meta-analyses
(NMAs) comparing biologic treatments in moderate to severe plaque psoriasis (PsO) …

Psoriasis and diabetes shared common underlying pathophysiological mechanisms.
Emerging data suggested that antidiabetic medications may improve the psoriasis severity …

BACKGROUND: Previous studies demonstrated substantial economic and comorbidity
burden associated with psoriasis (PsO) before biologics were available. Biologics have …

Background Despite the availability of a wide range of therapies for the systemic treatment of
moderate to severe psoriasis, many psoriasis patients do not receive adequate treatment …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Introduction ESPRIT (NCT00799877) is an ongoing 10-year international prospective
observational registry evaluating the long-term safety and effectiveness of originator …

Psoriasis is a complex and chronic disease, and, in most cases, therapies are required
during all patients' lifetime. The efficacy and safety profiles of biological therapies are well …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Psoriasis is an immune-mediated inflammatory dermatosis affecting 2 to 3%(1) of the world's
population. The therapeutic armamentarium has significantly evolved: since the 2000s, a …